Ostrowiec Swietokrzyskie, Poland Clinical Trials

A listing of Ostrowiec Swietokrzyskie, Poland clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
Featured trial
Pain Sensitivity and Unpleasantness in People with Alzheimer’s Disease and/or Cancer

The University of Tennessee Health Science Center in Memphis, TN has a research opportunity for people to participate in the study: Pain Sensitivity and Unpleasantness in People with Alzheimer’s Disease and Cancer. Specifically, they are looking for individuals over the age of 60 for 1 of 3 groups: (1) those …

primary cancer
Online studies
cancer
AIDS
University of Tennessee Health Science Center
(online study) Contact site
  • 41 views
  • 28 Sep, 2022
  • 1 location
  • Online study
Featured trial
ARE YOU CARING FOR A LOVED ONE WITH DEMENTIA OR MCI?

You may be eligible to participate in a research study evaluating the effects of a new in-hometechnology system for caregivers of people with dementia or mild cognitive impairment. Thestudy is being conducted by Dr. Robert Levenson (University of California, Berkeley,Department of Psychology) and Gene Wang (People Power Company of Care …

mild cognitive impairment
Online studies
dementia
cognitive impairment
alzheimer's disease
University of California, Berkeley
(online study) Contact site
  • 45 views
  • 29 Nov, 2022
  • 1 location
  • Online study
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

The purpose of this study is to assess the pharmacokinetics (PK), efficacy, and safety of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).

Galderma Investigational Site #5495
 (67.4 away) Contact site
  • 0 views
  • 04 Oct, 2022
  • +29 other locations
A Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) (VICTORION-2P)

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).

Novartis Investigative Site
 (32.4 away) Contact site
  • 1 views
  • 10 Oct, 2022
  • +661 other locations
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease

This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary disease (COPD) maintenance therapy in patients with COPD who are former or current smokers and have a history of frequent exacerbations.

Indywidualna Specjalistyczna Praktyka Lekarska lek.
 (35.0 away) Contact site
  • 5 views
  • 18 Oct, 2022
  • +180 other locations
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation (NOTUS)

Primary Objective: To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by Annualized rate of acute moderate or severe COPD exacerbation (AECOPD) Secondary Objectives: To evaluate the effect of dupilumab administered every 2 weeks on Pre-bronchodilator …

Investigational Site Number :6160010
 (65.7 away) Contact site
  • 51 views
  • 21 Oct, 2022
  • +307 other locations
Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level (MATINEE)

This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study designed to confirm the benefits of mepolizumab treatment on moderate or severe exacerbations in chronic obstructive pulmonary disease (COPD) participants given as an add on to their optimized maintenance COPD therapy. The maximum duration of participant participation is approximately 109 …

albuterol
antibiotics
fluticasone
eosinophil count
copd exacerbation
GSK Investigational Site
 (35.0 away) Contact site
  • 552 views
  • 04 Oct, 2022
  • +221 other locations
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1)

Primary Objective: Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD Secondary Objectives: Evaluate the efficacy of itepekimab compared with placebo on pulmonary function in former smokers with moderate-to-severe COPD Evaluate the efficacy of itepekimab compared …

Investigational Site Number :6160003
 (85.6 away) Contact site
  • 17 views
  • 07 Oct, 2022
  • +159 other locations
A Study of Lebrikizumab in Combination With Topical Corticosteroids in Participants Having Atopic Dermatitis (AD) That Are Not Adequately Controlled or Non-eligible for Cyclosporine

The main purpose of this study is to evaluate the efficacy of lebrikizumab compared with placebo in participants not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable up to Week 16.

topical agents
lebrikizumab
topical corticosteroid
corticosteroids
cyclosporine
Alm Site 39
 (55.6 away) Contact site
  • 0 views
  • 04 Oct, 2022
  • +46 other locations
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation (NOTUS)

Primary Objective: To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by Annualized rate of acute moderate or severe COPD exacerbation (AECOPD) Secondary Objectives: To evaluate the effect of dupilumab administered every 2 weeks on Pre-bronchodilator …

muscarinic antagonists
pulmonary function test
dyspnea
eosinophil count
copd exacerbation
Investigational Site Number :6160010
 (65.7 away) Contact site
  • 314 views
  • 25 Oct, 2022
  • +308 other locations